Trial Profile
An 8-week, Multicenter, Randomized, Double-blind, Placebo and Active-controlled, Parallel Group, Dose-ranging Study to Evaluate the Efficacy and Safety of 3 Doses of CHF 718 pMDI (HFA Beclomethasone Dipropionate Via Pressured Metered Dose Inhaler) in Asthmatic Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jun 2022
Price :
$35
*
At a glance
- Drugs Beclometasone (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms BEAM
- Sponsors Chiesi Farmaceutici
- 27 Jun 2022 Results assessing appropriate dose of beclomethasone dipropionate (BDP) to be used in a single-inhaler extrafine formulation triple combination of BDP, formoterol fumarate and glycopyrronium, published in the Journal of Asthma.
- 20 May 2020 Primary endpoint (Change from baseline in pre-dose morning FEV1 at Week 8) has been met, according to results presented at the 116th International Conference of the American Thoracic Society
- 20 May 2020 Results presented at the 116th International Conference of the American Thoracic Society